L’Azienda Ospedaliera Di Rilievo Nazionale Santobono-Pausilipon
- Address
- lock Available on a paid plan
Lymphatic Malformations – PI3K Targeted Therapy
The Divisione di Oncoematologia at L’Azienda Ospedaliera Di Rilievo Nazionale Santobono-Pausilipon is evaluating a new oral agent for patients with lymphatic malformations linked to a PIK3CA mutation. The study aims to assess radiological response and safety across children and adults.
- Investigating alpelisib efficacy in reducing lesion size
- Monitoring radiographic outcomes at 24 weeks
- Including participants from infancy to adulthood
This work contributes to the broader effort to bring precision medicine to rare vascular disorders in Europe.
Classical Hodgkin Lymphoma – Immunotherapy Evaluation
A phase II trial at the Naples hospital examines the combination of pembrolizumab with standard chemotherapy in children and young adults with classical Hodgkin lymphoma. Researchers are measuring the objective response rate using established IWG criteria.
- Assessing response in slow early responders
- Stratifying patients by risk groups
- Blinded independent central review of imaging
The goal is to improve first‑line treatment outcomes and reduce long‑term toxicity for this youthful population.
Haemophilia A – Innovative Prophylaxis Studies
Two linked studies at the site explore the safety of transitioning from emicizumab to the next‑generation bispecific antibody Mim8 in individuals with haemophilia A, with or without FVIII inhibitors. One trial focuses on the switch process, while the other follows long‑term use.
- Evaluating prophylactic efficacy during emicizumab washout
- Tracking inhibitor development over time
- Including both previously treated and untreated pediatric patients
Findings aim to broaden prophylactic options and enhance quality of life for patients across Europe.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Novo Nordisk A/S1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 566 other sites in Italy
Therapeutic Area Benchmark — Italy
Select a therapeutic area to compare against other sites in Italy.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Italy
Market Share
Country: Italy
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in L’Azienda Ospedaliera Di Rilievo Nazionale Santobono-Pausilipon
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Alpelisib in Pediatric and Adult Patients with PIK3CA-Mutated Lymphatic Malformations: A Randomized, Double-Blind, Placebo-Controlled Study | Novartis Pharma AG | Phase IV | Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Alpelisib | 1 | Unknown | 2024-02-07 | 2024-02-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.